GILD - GILEAD SCIENCES, INC.
117.41
1.370 1.167%
Share volume: 14,406,035
Last Updated: 03-07-2025
Research and Development in Biotechnology (except Nanobiotechnology):
-0.45%
PREVIOUS CLOSE
CHG
CHG%
$116.04
1.37
0.01%
Fundamental analysis
46%
Profitability
21%
Dept financing
43%
Liquidity
26%
Performance
78%
Performance
5 Days
2.33%
1 Month
22.97%
3 Months
29.61%
6 Months
48.30%
1 Year
55.88%
2 Year
48.71%
Key data
Stock price
$117.41
DAY RANGE
$114.79 - $118.42
52 WEEK RANGE
$62.07 - $118.42
52 WEEK CHANGE
$55.88
DIVIDEND
$0.77
EX-DIVIDEND DATE
06-14-2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: Daniel P. O'Day
Region: US
Website: gilead.com
Employees: 17,000
IPO year: 1992
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: gilead.com
Employees: 17,000
IPO year: 1992
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Gilead Sciences discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, and Atripla products for the treatment of HIV/AIDS.
Recent news